Table 3

Differences in change from baseline in 24 hours’ heartburn intensity scores

Heartburn intensity, LSM (SE)
Days 1–4Days 5–14Days 1–14
Full analysis set
Esomeprazole 20 mgn=330
0.76 (0.04)		n=325
0.63 (0.03)		n=330
0.68 (0.03)
Placebon=319
0.95 (0.03)		n=320
0.89 (0.03)		n=321
0.91 (0.03)
Difference (95% CI) between groups in change from baseline; p value−0.2 (−0.2 to −0.1);<0.001−0.2 (−0.3 to −0.1);<0.001−0.2 (−0.3 to −0.1);<0.001
 More frequent heartburn*
Esomeprazole 20 mgn=185
0.95 (0.05)		n=182
0.82 (0.05)		n=185
0.86 (0.04)
Placebon=189
1.18 (0.04)		n=191
1.13 (0.04)		n=191
1.15 (0.03)
Difference (95% CI) between groups in change from baseline; p value−0.2 (−0.3 to −0.1);<0.001−0.2 (−0.3 to −0.1);<0.001−0.2 (−0.3 to −0.1);<0.001
 Less frequent heartburn†
Esomeprazole 20 mgn=145
0.52 (0.04)		n=143
0.40 (0.03)		n=145
0.45 (0.04)
Placebon=130
0.62 (0.04)		n=129
0.54 (0.04)		n=130
0.56 (0.03)
Difference (95% CI) between groups in change from baseline; p value−0.1 (−0.3 to 0.0); 0.027−0.2 (−0.3 to −0.1);<0.001−0.2 (−0.3 to −0.1); 0.002

  • *More frequent heartburn defined as 6 or more days of heartburn during the run-in period.

  • †Less frequent heartburn defined as fewer than 6 days of heartburn during the run-in period.

  • LSM, least squares mean.